• Bridgebio Oncology Therapeutics released a corporate deck outlining three Phase 1 RAS-pathway programs with clinical data supporting continued development.
• Lead priority: BBO-8520 with pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC; ORR 75% at 500 mg QD.
• Across dose levels, the combination showed 53% ORR in G12C inhibitor-experienced patients; management highlighted a differentiated liver-safety profile.
• BBO-11818 pan-KRAS and BBO-10203 RAS:PI3Kα programs remain active; additional readouts flagged for Q4 2026 and mid-2027.
• Cash reported at USD 344 million at end-Q2 2026; runway projected into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.